American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate - Archive ouverte HAL Access content directly
Journal Articles British Journal of Dermatology Year : 2020

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate

, , , , (1, 2) , , , ,
1
2
A. Senchyna
  • Function : Author
S. Simon
  • Function : Author
H. Cissé
  • Function : Author
M. Ginouves
  • Function : Author
G. Alcoba
  • Function : Author
Magalie Pierre Demar
  • Function : Author
P. Couppie
  • Function : Author
R. Blaizot
  • Function : Author

Abstract

New World cutaneous leishmaniasis (CL) is endemic in many countries of Latin America, including French Guiana 1. While pentamidine is the first‐line treatment against Leishmania guyanensis in this territory 2, pentavalent antimonials such as meglumine antimoniate (MA) are recommended in case of L. braziliensis or pentamidine‐resistant strains of other species 2. Liposomal amphotericin B (L‐AmB) (Ambisome ®) is widely used against fungi and visceral leishmaniasis 3. However, data concerning its efficacy in New World CL are scarce and contradictory 4‐7. Due to a shortage in MA, the Cayenne Hospital started using L‐AmB as an alternative in 2015. We conducted a retrospective study to compare efficacy and safety of L‐AmB and MA in patients treated for CL.

Dates and versions

hal-03282671 , version 1 (09-07-2021)

Identifiers

Cite

A. Senchyna, S. Simon, H. Cissé, M. Ginouves, Ghislaine Prevot, et al.. American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate. British Journal of Dermatology, 2020, 183 (2), pp.389-391. ⟨10.1111/bjd.18964⟩. ⟨hal-03282671⟩

Collections

RIIP CNRS GUYANE
12 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More